Changes

Jump to: navigation, search

Prostate Cancer Clinical Trials

7,063 bytes added, 05:07, 7 October 2011
To go back to the main page, click [http://dolcera.com/wiki/index.php?title=Cancer_Vaccines_-_Clinical_Trial_Analysis#Prostate_Cancer_2 here]
<br>
<br>

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''S.No.'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Drug Name'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Biological Name'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Developer'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Current Development Phase'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Additional Information'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Start Date'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Completion Date'''</font>
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Source'''</font>
|-
|align = "center" bgcolor = "#DBE5F1"|11
|bgcolor = "#DBE5F1"|Detox-B adjuvant, ras peptide cancer vaccine
|align = "center" bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|bgcolor = "#DBE5F1"|National Cancer Institute (NCI)
|align = "center" bgcolor = "#DBE5F1"|I
|bgcolor = "#DBE5F1"|Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.
|bgcolor = "#DBE5F1"|1995
|bgcolor = "#DBE5F1"|Ongoing
|bgcolor = "#DBE5F1"|<font color="#0000FF"><u>Source</u></font>
|-
|align = "center"|12
|Detox-B adjuvant, ras peptide cancer vaccine
|align = "center"|<nowiki>-</nowiki>
|National Cancer Institute (NCI)
|align = "center"|I
|Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.
|1995
|Ongoing
|<font color="#0000FF"><u>Source</u></font>
|-
|align = "center" bgcolor = "#DBE5F1"|13
|bgcolor = "#DBE5F1"|Detox-B adjuvant, ras peptide cancer vaccine
|align = "center" bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|bgcolor = "#DBE5F1"|National Cancer Institute (NCI)
|align = "center" bgcolor = "#DBE5F1"|I
|bgcolor = "#DBE5F1"|Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.
|bgcolor = "#DBE5F1"|1995
|bgcolor = "#DBE5F1"|Ongoing
|bgcolor = "#DBE5F1"|<font color="#0000FF"><u>Source</u></font>
|-
|align = "center"|14
|Detox-B adjuvant, ras peptide cancer vaccine
|align = "center"|<nowiki>-</nowiki>
|National Cancer Institute (NCI)
|align = "center"|I
|Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.
|1995
|Ongoing
|<font color="#0000FF"><u>Source</u></font>
|-
|align = "center" bgcolor = "#DBE5F1"|15
|bgcolor = "#DBE5F1"|Detox-B adjuvant, ras peptide cancer vaccine
|align = "center" bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|bgcolor = "#DBE5F1"|National Cancer Institute (NCI)
|align = "center" bgcolor = "#DBE5F1"|I
|bgcolor = "#DBE5F1"|Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.
|bgcolor = "#DBE5F1"|1995
|bgcolor = "#DBE5F1"|Ongoing
|bgcolor = "#DBE5F1"|<font color="#0000FF"><u>Source</u></font>
|-
|align = "center"|16
|Detox-B adjuvant, ras peptide cancer vaccine
|align = "center"|<nowiki>-</nowiki>
|National Cancer Institute (NCI)
|align = "center"|I
|Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.
|1995
|Ongoing
|<font color="#0000FF"><u>Source</u></font>
|-
|align = "center" bgcolor = "#DBE5F1"|17
|bgcolor = "#DBE5F1"|HyperAcute Pancreas
|align = "center" bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|bgcolor = "#DBE5F1"|NewLink Genetics
|align = "center" bgcolor = "#DBE5F1"|II
|bgcolor = "#DBE5F1"|The purpose of this study is to assess overall survival after treatment with a regimen of adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.
|bgcolor = "#DBE5F1"|2010
|bgcolor = "#DBE5F1"|2014
|bgcolor = "#DBE5F1"|<font color="#0000FF"><u>[http://clinicaltrials.gov/ct2/show/NCT01072981?term=HyperAcute+Pancreas&rank=1 Source]</u></font>
|-
|align = "center"|18
|<nowiki>-</nowiki>
|HyperAcute(R)-Pancreatic Cancer Vaccine
|NewLink Genetics
|align = "center"|II
|To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with chemotherapy and chemoradiation.
|2007
|2011
|<font color="#0000FF"><u>[http://clinicaltrials.gov/ct2/show/NCT00569387?term=cancer+vaccine&rank=6 Source]</u></font>
|-
|align = "center" bgcolor = "#DBE5F1"|19
|bgcolor = "#DBE5F1"|cyclophosphamide
|bgcolor = "#DBE5F1"|GVAX pancreatic cancer vaccine
|bgcolor = "#DBE5F1"|Sidney Kimmel Comprehensive Cancer Center, National Cancer Institute (NCI)
|align = "center" bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|bgcolor = "#DBE5F1"|This randomized clinical trial is studying the side effects of vaccine therapy and to see how well it works when given with or without cyclophosphamide in treating patients undergoing chemotherapy and radiation therapy for stage I or stage II pancreatic cancer that can be removed by surgery.
|bgcolor = "#DBE5F1"|2008
|bgcolor = "#DBE5F1"|2012
|bgcolor = "#DBE5F1"|<font color="#0000FF"><u>[http://clinicaltrials.gov/ct2/show/NCT00727441?term=cancer+vaccine&rank=11 Source]</u></font>
|-
|align = "center"|20
|Ipilimumab
|PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine
|Sidney Kimmel Comprehensive Cancer Center, National Cancer Institute (NCI)
|align = "center"|I
|To determine the safety profile of ipilimumab alone or in combination with a pancreatic cancer vaccine in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.
|2009
|2011
|<font color="#0000FF"><u>[http://clinicaltrials.gov/ct2/show?term=cancer+vaccine&rank=91 Source]</u></font>
|-
|align = "center" bgcolor = "#DBE5F1"|21
|bgcolor = "#DBE5F1"|<nowiki>-</nowiki>
|bgcolor = "#DBE5F1"|GI-4000 Vaccine <nowiki>+</nowiki> Activated T Cells, Surgical Evaluation after Vaccine <nowiki> </nowiki>4
|bgcolor = "#DBE5F1"|University of Pennsylvania
|align = "center" bgcolor = "#DBE5F1"|I
|bgcolor = "#DBE5F1"|The purpose of this study is to determine if it is safe to add multiple immunotherapies to standard chemotherapy and radiation for treating pancreatic cancer tumors that cannot be completely removed by surgery
|bgcolor = "#DBE5F1"|2008
|bgcolor = "#DBE5F1"|2009
|bgcolor = "#DBE5F1"|<font color="#0000FF"><u>[http://clinicaltrials.gov/ct2/show/NCT00837135?term=GI-4000&rank=1 Source]</u></font>
|-
|}

<br>
<br>
To go back to the main page, click [http://dolcera.com/wiki/index.php?title=Cancer_Vaccines_-_Clinical_Trial_Analysis#Prostate_Cancer_2 here]
Sonal.pingle
111
edits
Retrieved from "https://www.dolcera.com/wiki/index.php?title=Special:MobileDiff/9812"